A US researcher studied 3D structures of brain cells and connections, revealing new role for oligodendrocyte precursor cells (OPCs), in mice.
List view / Grid view
Baylor College of Medicine
Drug Target Review’s Ria Kakkad recently visited ELRIG and the British Pharmacological Society’s conference on New Modalities in Pharmacology and Drug Discovery which took place in London, UK. This article shares some of the key takeaways from the event.
Researchers have found that genetically and pharmacologically restoring the normal activity of the brain circuit improved anorexia, opening the possibility of developing a treatment strategy for affected individuals in the future.
Using nose organoids, researchers have highlighted key differences between the infection by SARS-CoV-2 and that of respiratory syncytial virus.
New research has shown that one-time infusion of stem cells from bone marrow improves the survival of mice with sepsis.
New technology system of drug-based markers for the selection or counter-selection of genes may advance genetic screening methods.
Researchers use fast and cost-effective technology to identify the viral protein inhibitor Mpro as a potential drug against COVID-19.
A new model that closely resembles aged lung epithelium in idiopathic pulmonary fibrosis has been developed, possibly leading to treatments.
NPSR1 has been identified as a genetic cause of endometriosis, revealing a potential drug target that may lead to better therapies.
New research by US institutions in pigs shows that knocking down a particular signalling pathway after heart failure renews heart tissue.
Scientists have found differences in 206 genes between the GRCh38 (hg38) and GRCh37 (hg19) human reference genomes.
Researches have provided a proof-of-concept that proteomic analysis could be used to identify drivers of aggressive cancers.
Research has shown that MAPK4 activates two molecules in cellular signalling pathways involved in prostate cancer growth.
A study has shown that the ES17 phage binds to heparan sulphate and can target and eliminate ExPEC bacteria in animal models.
A team has found that a mutation in the ATAXIN-1 gene causes spinocerebellar ataxia type 1 (SCA1), presenting a drug target for the condition.